Skip to content

Efficacy of Multidimensional Management of Mild Traumatic Brain Injury

Efficacy of Multidimensional Management of Mild Traumatic Brain Injury : A Randomised Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03811626
Enrollment
221
Registered
2019-01-22
Start date
2012-04-01
Completion date
2013-06-30
Last updated
2019-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Traumatic Brain Injury

Keywords

Mild TBI, quality of life, coping strategies, symptoms, neuropsychological tests, pain, memory reactive, Cognitive dimension

Brief summary

Unfavorable outcomes (UO) are seen in 15 to 20% of patients with mild traumatic brain injury (mTBI). Early identification of patients at risk for UO is crucial for suitable management to be initiated, increasing their chances for a return to a normal life. The investigators previously developed a diagnostic tool enabling early identification (8 to 21 days after the injury) of patients likely to develop UO. In the present study, the investigators examined the value and beneficial effects of early multidimensional management (MM) on prognosis. The investigators used a diagnostic tool to classify 221 mTBI patients as UO (97) or FO (favorable outcome) (124). Patients whose initial risk factors point to UO are at risk of developing post-concussion syndrome (PCS). UO patients were randomized into 2 groups: a group that underwent MM (cognitive-behavioral rehabilitation) (34) and a group with no specific management (46). At 6 months, these 2 groups were compared and the impact of MM on outcome was assessed. Among patients initially classified as FO (101), 95% had FO at 6 months and only 5 had PCS as defined by DSM-IV classification. Of the UO patients who received MM, 94% had no PCS 6 months after injury, whereas 52% of the UO patients who did not receive MM had persistent PCS. The effect of MM on the recovery of patients at 6 months, once adjusted for the main confounding factors, was statistically significant (p\<0.001). These results show that the initiation of MM after early identification of at-risk mTBI patients can considerably improves their prognosis.

Interventions

Combination of clinical examination and neuropsychological and psychological tests

Sponsors

Institut de Recherche sur la Moelle épinière et l'Encéphale
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

\- Patients aged 18 to 65 who have suffered mTBI, have health care coverage, who understand French, who can be followed for 6 months, and who are able to understand, reply, and cooperate.

Exclusion criteria

* Patient intubated and/or ventilated and/or sedated upon arrival at hospital * Patient with injury to the medulla and with neurological signs or multiple injuries (at least 1 of which is life-threatening) * Brain injury incurred during a suicide attempt * Patient presenting psychiatric or psychological disorders that are debilitating and/or interfere with follow-up and/or evaluation * Psychoactive treatment ongoing at the time of injury * History of hospitalization in specialized a psychiatric setting and/or sick leave for psychological reasons * Patient with a neurological disorder * Patient with substance dependence * Subject under guardianship or wardship

Design outcomes

Primary

MeasureTime frameDescription
Change in quality of lifeBaseline, 6 months -Change in quality of life assessed by QOLIBRI (Quality of Life after Brain Injury) Scale - QOLIBRI scale assess health-related quality of life (HRQoL) of individuals after traumatic brain injury. QOLIBRI is a comprehensive questionnaire with 37 items covering six dimensions of HRQoL after TBI. The QOLIBRI scores are reported on a 0-100 scale , where 0=worst possible quality of life and 100=best possible quality of life.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026